Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Manganese chloride tetrahydrate (CMC-001) enhanced liver MRI: evaluation of efficacy and safety in healthy volunteers.

Albiin N, Kartalis N, Bergquist A, Sadigh B, Brismar TB.

MAGMA. 2012 Oct;25(5):361-8. Epub 2012 Mar 8.

PMID:
22399275
2.

Manganese-based oral contrast agent for liver magnetic resonance imaging: evaluation of the time course and dose response of liver signal intensity enhancement.

Rief M, Huppertz A, Asbach P, Franiel T, Schwenke C, Hamm B, Taupitz M, Wagner M.

Invest Radiol. 2010 Sep;45(9):565-71. doi: 10.1097/RLI.0b013e3181e9e120.

PMID:
20644484
3.

MRI of colorectal cancer liver metastases: comparison of orally administered manganese with intravenously administered gadobenate dimeglumine.

Brismar TB, Kartalis N, Kylander C, Albiin N.

Eur Radiol. 2012 Mar;22(3):633-41. doi: 10.1007/s00330-011-2288-y. Epub 2011 Sep 28.

4.

A new manganese-based oral contrast agent (CMC-001) for liver MRI: pharmacological and pharmaceutical aspects.

Jørgensen JT, Rief M, Brismar TB, Wagner M, Albiin N.

Acta Radiol. 2012 Sep 1;53(7):707-13. doi: 10.1258/ar.2012.120034. Epub 2012 Jul 20. Review.

PMID:
22821959
5.

Effect of new manganese contrast agent on tissue intensities in human volunteers: comparison of 0.23, 0.6 and 1.5 T MRI, a part of a phase I trial.

Chabanova E, Thomsen HS, Løgager V, Moller JM, Brage K, Fogh K, Bovin J, Elmig J.

MAGMA. 2004 Sep;17(1):28-35. Epub 2004 Jul 16.

PMID:
15258827
6.

Imaging liver metastases with a new oral manganese-based contrast agent.

Chabanova E, Logager V, Moller JM, Dekker H, Barentsz J, Thomsen HS.

Acad Radiol. 2006 Jul;13(7):827-32.

PMID:
16777556
7.

Oral manganese for liver imaging at three different field strengths.

Thomsen HS, Loegager V, Noergaard H, Chabanova E, Moller JM, Sonne J.

Acad Radiol. 2004 Jun;11(6):630-6.

PMID:
15172365
8.
10.

Initial clinical experience with oral manganese (CMC-001) for liver MR imaging.

Thomsen HS, Barentsz JO, Burcharth F, Chabanova E, Dekker HM, Moesgaard F, Moller JM, Leth-Espensen P, Logager V, Takahashi S.

Eur Radiol. 2007 Jan;17(1):273-8. Epub 2006 Jun 9.

PMID:
16763790
11.
12.

High spatial resolution, respiratory-gated, t1-weighted magnetic resonance imaging of the liver and the biliary tract during the hepatobiliary phase of gadoxetic Acid-enhanced magnetic resonance imaging.

Lee ES, Lee JM, Yu MH, Shin CI, Woo HS, Joo I, Stemmer A, Han JK, Choi BI.

J Comput Assist Tomogr. 2014 May-Jun;38(3):360-6. doi: 10.1097/RCT.0000000000000055.

PMID:
24681858
13.

A multicenter, randomized, double-blind study to evaluate the safety, tolerability, and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (gadopentetate dimeglumine) in patients with liver pathology: results of a Phase III clinical trial.

Rubin DL, Desser TS, Semelka R, Brown J, Nghiem HV, Stevens WR, Bluemke D, Nelson R, Fultz P, Reimer P, Ho V, Kristy RM, Pierro JA.

J Magn Reson Imaging. 1999 Feb;9(2):240-50.

PMID:
10077020
14.

Intraindividual Crossover Comparison of Gadoxetic Acid Dose for Liver MRI in Normal Volunteers.

Motosugi U, Bannas P, Hernando D, Salmani Rahimi M, Holmes JH, Reeder SB.

Magn Reson Med Sci. 2016;15(1):60-72. doi: 10.2463/mrms.2015-0005. Epub 2015 Jun 23.

15.

Safety of gadoxetate disodium: Results from the clinical phase II-III development program and postmarketing surveillance.

Endrikat JS, Dohanish S, Balzer T, Breuer JA.

J Magn Reson Imaging. 2015 Sep;42(3):634-43. doi: 10.1002/jmri.24838. Epub 2015 Feb 2.

PMID:
25643844
16.

A multisite phase III study of the safety and efficacy of a new manganese chloride-based gastrointestinal contrast agent for MRI of the abdomen and pelvis.

Small WC, DeSimone-Macchi D, Parker JR, Sukerkar A, Hahn PF, Rubin DL, Zelch JV, Kuhlman JE, Outwater EK, Weinreb JC, Brown JJ, de Lange EE, Woodward PJ, Arildsen R, Foster GS, Runge VM, Aisen AM, Muroff LR, Thoeni RF, Parisky YR, Tanenbaum LN, Totterman S, Herfkens RJ, Knudsen J, Bernardino ME, et al.

J Magn Reson Imaging. 1999 Jul;10(1):15-24.

PMID:
10398973
17.

Combined gadoxetic acid and gadofosveset enhanced liver MRI: A feasibility and parameter optimization study.

Bannas P, Motosugi U, Hernando D, Rahimi MS, Holmes JH, Reeder SB.

Magn Reson Med. 2016 Jan;75(1):318-28. doi: 10.1002/mrm.25554. Epub 2015 Feb 3.

PMID:
25648403
18.

The diagnostic efficacy of quantitative liver MR imaging with diffusion-weighted, SWI, and hepato-specific contrast-enhanced sequences in staging liver fibrosis--a multiparametric approach.

Feier D, Balassy C, Bastati N, Fragner R, Wrba F, Ba-Ssalamah A.

Eur Radiol. 2016 Feb;26(2):539-46. doi: 10.1007/s00330-015-3830-0. Epub 2015 May 21.

PMID:
25991488
19.
20.

Supplemental Content

Support Center